GLP-1 Market
LLY $1406.29 ▼ -1.8% NVO $40.70 ▼ -2.2% PFE $28.41 ▼ -1.6% VKTX $26.65 ▼ -0.6% KLRA $12.08 ▼ -3.9% GPCR $18.06 ▼ -2.7% RHHBY $60.95 ▲ +1.1%
Market data delayed up to 20 min · Source: Twelve Data
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

DLBS3233

DLBS3233

Company
Dexa Medica Group
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Nov 17, 2026

Find a Clinical Trial Near Me

See recruiting studies for DLBS3233 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07403201

    The Effect of Therapy Combination in PCOS With Dlbs 3233

    Not yet reported Inlacinpenelitian 90 participants Est. completion 2026-01-31 1 site Stand-alone
    Other conditions: Polycystic Ovary Syndrome
    View official trial listing →
  • Completed NCT NCT01472614

    Efficacy and Safety of Add-on Therapy With DLBS3233 in Patients With Type-2 Diabetes Mellitus

    Not yet reported Dexa Medica Group 54 participants Est. completion 2013-04 2 sites Stand-alone
    Other conditions: Type-2 Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT01531933

    Efficacy and Safety of DLBS3233 in Prediabetic Patients

    Not yet reported Dexa Medica Group 80 participants Est. completion 2012-07 1 site Stand-alone
    Other conditions: Prediabetic
    View official trial listing →
  • Completed NCT NCT01645332

    Efficacy and Safety of DLBS3233 in Subjects With New Onset of Type 2 Diabetes Mellitus

    Not yet reported Dexa Medica Group 104 participants Est. completion 2014-09 1 site Stand-alone
    Other conditions: Type-2-diabetes Mellitus, New Onset
    View official trial listing →
  • Completed NCT NCT01733459

    Efficacy and Safety of DLBS3233 in Subjects With Polycystic Ovary Syndrome (PCOS)

    Not yet reported Dexa Medica Group 124 participants Est. completion 2018-06 2 sites Stand-alone
    Other conditions: Polycystic Ovary Syndrome (PCOS)
    View official trial listing →
  • Completed NCT NCT01999686

    PCOS Treatment Using DLBS3233, Metformin, and Combination of Both

    Not yet reported Dexa Medica Group 186 participants Est. completion 2019-05 7 sites Stand-alone
    Other conditions: Polycystic Ovary Syndrome (PCOS), Insulin Resistance
    View official trial listing →
  • Completed NCT NCT07937449

    The Efficacy and Safety of DLBS3233 in Adults With Prediabetes

    Not yet reported Dexa Medica Group 120 participants Est. completion 2026-10-15 2 sites Stand-alone
    Prediabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: DLBS3233, Inlacin

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.